Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 2/2012

01-02-2012 | Meeting report

From cell regulation to patient survival: 2nd Cancer immunotherapy and immunomonitoring (CITIM) meeting, Budapest, 2–5 May 2011

Authors: Viktor Umansky, Anatoli Malyguine, Beatrix Kotlan, Natalia Aptsiauri, Michael R. Shurin

Published in: Cancer Immunology, Immunotherapy | Issue 2/2012

Login to get access

Excerpt

The 2nd International Conference “Cancer Immunotherapy and Immunomonitoring (CITIM)” took place in Budapest, Hungary, and was organized by the International (Chair—Michael Shurin) and Local (Chair—Beatrix Kotlan) Organizing Committees. The main aim was to bring the world’s best tumor immunologists to Budapest to discuss the mechanisms of immune regulation in the tumor microenvironment, the efficacy of anticancer immunotherapeutic modalities, the results of clinical trials and the methods of patients’ immunomonitoring. This report provides a short overview of novel concepts, strategies and clinical achievements in this quickly developing field of oncology since the first CITIM meeting held in Kiev, Ukraine, in 2009. Almost 200 participants from more than 30 countries of Europe, Asia, Africa, North and South America as well as from Australia were attracted by the scientific program that consisted of presentations from 58 international experts. Good memories remain from the lively discussions of ten plenary sessions, four Keynote lectures, two special plenary presentations, best abstract award session and 75 posters. …
Metadata
Title
From cell regulation to patient survival: 2nd Cancer immunotherapy and immunomonitoring (CITIM) meeting, Budapest, 2–5 May 2011
Authors
Viktor Umansky
Anatoli Malyguine
Beatrix Kotlan
Natalia Aptsiauri
Michael R. Shurin
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 2/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1115-2

Other articles of this Issue 2/2012

Cancer Immunology, Immunotherapy 2/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine